BioCardia Presents at Alliance for Regenerative Medicine's (ARM's) Annual Cell & Gene Therapy Investor Day

Thursday, April 19, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN CARLOS, Calif., April 18, 2018 /PRNewswire/ -- BioCardia®, Inc., [OTC: BCDA] a leader in cardiovascular regenerative

medicine, today announced that it was among the companies providing presentations at the Alliance for Regenerative Medicine's (ARM's) 6th Annual Cell & Gene Therapy Investor Day in New York City.
Peter Altman
, Ph.D., BioCardia President and CEO, presented a corporate overview at the conference.

ARM's Cell & Gene Therapy Investor Day A recording of the company's presentation at the Cell & Gene Therapy Investor Day will be available at http://arminvestorday.com/webcast/.

About BioCardia BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Company's biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

About the Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 290 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Investor Contact:David McClung, Chief Financial OfficerEmail: investors@BioCardia.comPhone: 650-226-0120

Media Contact:David Schull | Alex XenakisEmail:  david.schull@russopartnersllc.com | alex.xenakis@russopartnersllc.comPhone: 212-845-4271 | 212-845-4226

Cision View original content:http://www.prnewswire.com/news-releases/biocardia-presents-at-alliance-for-regenerative-medicines-arms-annual-cell--gene-therapy-investor-day-300631937.html

SOURCE BioCardia, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store